Frontotemporal Disorders Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Frontotemporal Disorders Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The Frontotemporal Disorders Treatment market studied is anticipated to grow with a CAGR of nearly 7.2%, during the forecast period.

Certain factors that are driving the market growth include growing prevalence of dementia and other frontotemporal disorders, increasing drug development grants and funding by government as well as non-government organisations.

Increasing prevalence of target disease and growing geriatric population suffering from these diseases are expected to promote the growth of the market. According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth.

The increasing government funding for the target disease care, support, and research activities is estimated to fuel the growth of this industry. Various organizations involved in this activity include the National Institute of Health (NIH), Alzheimer’s Association, and National Institute on Aging. In 2019, the NIH has spent around USD 387 million on research projects for Alzheimer's Disease Related Dementias (ADRD). These initiatives are anticipated to provide this market with growth opportunities. However, lack of awareness regarding target disease in developing country may restrict the market.

• Antidepressant drugs are used for the treatment of major depressive disorders and other conditions, including dysthymia, anxiety disorders, obsessive-compulsive disorder (OCD), eating disorders, chronic pain, neuropathic pain, etc.
• In October 2018, Lundbeck has launched Brintellix tablets, which are used for the treatment of Major Depressive Disorder in India. Similarly, in April 2019, Lupin has launched antidepressant Fluoxetine tablets in the American market. The tablets are indicated for the treatment of the major depressive disorder, obsessive-compulsive disorder.
• Thus, owing to the rising number of the patient pool and recent product launches the market is expected to witness high growth across the globe over the forecast period.

• North America dominated with revenue estimated as a result of the presence of sophisticated healthcare facilities and infrastructure in developed countries, such as the U.S. High purchasing power for expensive drugs, reimbursement policies and increasing patient pool are the drivers projected to boost the market demand.
• As per the National Institute of Neurological Disorders and Stroke, Alzheimer’s disease alone, as one dementia disorder, affects more than 5 million people in the U.S. The toll on individuals, caregivers and society is enormous and is expected to increase as the population ages. This aids in supplementing the regional growth.
• The Asia Pacific is expected to witness the fastest growth over the forecast period owing to the rising disposable income level. In addition, the high prevalence of the target diseases due to the growing geriatric population base coupled with the weak immune system is attributed to the growth of this industry.

The Frontotemporal Disorders Treatment market is competitive and consists of a few major players. Companies like Apotex Inc., AstraZeneca plc., Auro Pharma, Johnson & Johnson, Mylan N.V., Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals USA, Inc., among others, hold the substantial market share in the market. And in the coming years, few other players are also expected to enter into the market.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support